+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Polycythemia Vera - Pipeline Review, H1 2020

  • ID: 5007662
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 129 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Imago BioSciences Inc
  • Incyte Corp
  • MORE
Polycythemia Vera - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Polycythemia Vera - Pipeline Review, H1 2020, provides an overview of the Polycythemia Vera (Oncology) pipeline landscape.

Polycythemia Vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness and excessive sweating. The risk of polycythemia vera increases with age. Treatment includes alkylating agents.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Polycythemia Vera - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Polycythemia Vera (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycythemia Vera (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 9, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Polycythemia Vera (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Polycythemia Vera (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Polycythemia Vera (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Polycythemia Vera (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Polycythemia Vera (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Polycythemia Vera (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Polycythemia Vera (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Polycythemia Vera (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Imago BioSciences Inc
  • Incyte Corp
  • MORE
  • Introduction
  • Polycythemia Vera - Overview
  • Polycythemia Vera - Therapeutics Development
  • Polycythemia Vera - Therapeutics Assessment
  • Polycythemia Vera - Companies Involved in Therapeutics Development
  • Polycythemia Vera - Drug Profiles
  • Polycythemia Vera - Dormant Projects
  • Polycythemia Vera - Discontinued Products
  • Polycythemia Vera - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Polycythemia Vera, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Polycythemia Vera - Pipeline by AbbVie Inc, H1 2020
  • Polycythemia Vera - Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Polycythemia Vera - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
  • Polycythemia Vera - Pipeline by Gilead Sciences Inc, H1 2020
  • Polycythemia Vera - Pipeline by Imago BioSciences Inc, H1 2020
  • Polycythemia Vera - Dormant Projects, H1 2020
  • Polycythemia Vera - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Polycythemia Vera, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie Inc
  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Imago BioSciences Inc
  • Incyte Corp
  • IO Biotech ApS
  • Italfarmaco SpA
  • Kartos Therapeutics Inc
  • Merganser Biotech Inc
  • PharmaEssentia Corp
  • Protagonist Therapeutics Inc
  • Sino Biopharmaceutical Ltd
Note: Product cover images may vary from those shown
Adroll
adroll